China
Africa
Explore chapters and articles related to this topic
Fibromyalgia
Published in Michael S. Margoles, Richard Weiner, Chronic PAIN, 2019
The symptoms of malaise, fatigue, myalgia, and arthralgia accompany many connective tissue diseases. Patients with early rheumatoid arthritis may have a positive test for rheumatoid factor despite evanescent physical findings of synovitis or other evidence of articular inflammation. The response of the patient with rheumatoid arthritis to large doses of salicylates is greater than that of the patient with FS, although the latter may obtain some relief.
The small intestine and vermiform appendix
Published in Michael Gaunt, Tjun Tang, Stewart Walsh, General Surgery Outpatient Decisions, 2018
Perform a general examination. Examine for signs of weight loss and anaemia. Examine for general features of connective tissue disease. Abdominal examination may be normal but rectal examination may reveal melaena.
Animal Models Of Connective Tissue Diseases
Published in Marcos Rojkind, Connective Tissue in Health and Disease, 2017
Gerald Α. Hegreberg, Lynetta J. Freeman
Several previous reports have discussed the comparative aspects of connective tissue diseases.6-8 It is the intent of this chapter to present both established and emerging animal models of connective tissue diseases. This chapter has been structured to include both inherited and induced disorders of connective tissue. Major headings and subheadings include disease processes at different levels of biological organization, i.e., collagen diseases vs. arteriosclerosis.
Identification and management of connective tissue disease-associated interstitial lung disease: evidence-based Japanese consensus statements
Published in Expert Review of Respiratory Medicine, 2023
Masataka Kuwana, Masashi Bando, Yutaka Kawahito, Shinji Sato, Takafumi Suda, Yasuhiro Kondoh
Connective tissue diseases (CTDs) comprise a large group of systemic disorders characterized by dysfunction of multiple organ systems due to inflammation and fibrosis. In patients with CTDs, respiratory complications are frequent, with interstitial lung disease (ILD) being the most common [1]. ILD occurs in patients with various CTDs, including rheumatoid arthritis (RA), polymyositis/dermatomyositis (PM/DM), Sjögren’s syndrome, systemic sclerosis (SSc), systemic lupus erythematosus, and mixed connective tissue disease (MCTD) [1,2]. ILD is the leading cause of premature mortality in RA [3,4], PM/DM [5,6], Sjögren’s syndrome, SSc [7,8], and MCTD [9]. The onset, progression speed, treatment response, and prognosis of CTD-ILDs are highly variable among patients; some develop rapidly or slowly progressive course, leading to mortality, and others have stable ILD with no clinically meaningful progression during the course of the disease. Furthermore, respiratory complications may also arise from infection and drug-induced lung injury, which often make diagnosis, evaluation, and treatment of ILD difficult. Thus, for both pulmonologists and rheumatologists, personalized management is essential for improving outcomes in patients with CTD-ILD.
An IPF-like disease course in disorders other than IPF: how can this be anticipated, recognized, and managed?
Published in Expert Review of Clinical Immunology, 2021
Athol U. Wells, Vasileios Kouranos
Similarly, in the designation of IPF-like progression as progression despite treatment, no rigid definition of the choice and duration of historical therapies can be specified. For the most part, historical management has consisted of various forms of immunomodulation, along with the removal of occupational and environmental triggers. In the real world, many patients have major corticosteroid or immunosuppressant side-effects with disruption of planned treatment regimens. Patient choice, sometimes influenced by a major aversion to corticosteroid therapy, must be taken into account. The use of individual second line agents varies between diseases and is not, for the most part, informed by trials with definitive controlled evaluation. In patients with connective tissue disease, there are variable changes in regimens due to the impact of progressive systemic disease.
Presence of anti-TIF-1γ, anti-Ro52, anti-SSA/Ro60 and anti-Su/Ago2 antibodies in breast cancer: a cross-sectional study
Published in Immunopharmacology and Immunotoxicology, 2021
Mónica Vázquez-Del Mercado, Erika Aurora Martínez-García, Adrián Daneri-Navarro, Eduardo Gómez-Bañuelos, Beatriz Teresita Martín-Márquez, Oscar Pizano-Martínez, Eduardo A. Wilson-Manríquez, Esther Guadalupe Corona-Sánchez, Efrain Chavarria-Avila, Flavio Sandoval-García, Minoru Satoh
The clinical stage, hormonal stage (perimenopausal, menopausal and postmenopausal) [8], histopathology diagnosis (including cancer subtype) and immunohistochemistry (IHC) for estrogen receptor (ER), progesterone receptor (PgR), human epidermal growth factor receptor 2 (Her2/Neu) and triple negative status [9–11] were obtained from the clinical charts. Histopathology of breast cancer was classified by two experts and in case of major discordance, a third expert evaluated the biopsy. The classification included the following categories: ductal invasive, lobular invasive, medullar invasive, intraductal, mixed (ductal-lobular) invasive, papillar adenocarcinoma, ductal microinvasive, mucinous invasive, ductal in situ and unknown. Clinical evidence for a connective tissue disease was systematically obtained by retrospective chart review.